首页> 外文期刊>Journal of cardiac failure >Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device.
【24h】

Apoptosis, Bcl-2, and proliferating cell nuclear antigen in the failing human heart: observations made after implantation of left ventricular assist device.

机译:衰竭的人心脏中的凋亡,Bcl-2和增殖性细胞核抗原:植入左心室辅助装置后的观察结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Heart failure is characterized by progressive left ventricular remodeling, a complex process that results from cell growth and cell death. The quantitative contribution of apoptotic cells toward left ventricular remodeling has varied widely in tissue removed from cardiomyopathic hearts. Apoptosis has been responsive to angiotensin-converting enzyme inhibition in experimental heart failure, but the dynamics and responsiveness to chronic left ventricular unloading have not been studied. METHODS AND RESULTS: We studied 8 patients with severe heart failure before and after chronic left ventricular unloading with a left ventricular assist device (LVAD). Tissue from the left ventricular apex removed at the time of LVAD implantation was examined for apoptosis using the technique of terminal deoxynucleotidyl transferase deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) in 10 patients. These same hearts explanted at the time of cardiac transplantation were then examined for apoptosis after patients had been on the LVAD for 99 +/- 20 (SEM) days. An additional 10 patients with equally severe heart failure who underwent heart transplantation without the use of an LVAD served as controls. Eight hearts obtained at autopsy approximately 6 hours after death from patients who died of non-cardiovascular disease causes served as non-heart failure controls. Additionally, 6 hearts were examined by immunohistochemistry for the antiapoptotic protein, Bcl-2, and for the repair and/or proliferation marker, proliferating cell nuclear antigen (PCNA), before and after LVAD. Apoptosis was not detected in the tissue sections from the hearts of 8 patients at the time of LVAD implantation. Only 1 of these patients had limited apoptosis (< 1 apoptotic cell/1,000 myocytes) after LVAD insertion. Three of 10 patients with severe heart failure who did not receive an LVAD but underwent transplantation showed limited apoptosis (< 1 apoptotic cell/1,000 myocytes). Likewise, none of the control hearts from patients who died of noncardiovascular disease manifested apoptosis. Six of 6 patients overexpressed Bcl-2 at the time of LVAD insertion. In all these patients, Bcl-2 returned to negligible levels after chronic unloading of the heart. Likewise, PCNA was abundantly expressed in 5 of 6 failing hearts at the time of LVAD implantation and was reduced in 4 of 5 hearts after chronic unloading by LVAD. CONCLUSION: Apoptosis is a rare or inconsistent finding in the failing human heart. Overexpression of such indicators of cellular stress and DNA replication and/or repair as Bcl-2 and PNCA in heart failure may be altered by optimizing left ventricular loading conditions by such mechanical devices as the LVAD.
机译:背景:心力衰竭的特征是进行性左心室重构,这是由细胞生长和细胞死亡导致的复杂过程。从心肌病性心脏中取出的组织中,凋亡细胞对左心室重构的定量贡献变化很大。细胞凋亡对实验性心力衰竭中的血管紧张素转换酶抑制有响应,但尚未研究对慢性左心室卸载的动力学和响应性。方法和结果:我们研究了8例严重心力衰竭的慢性左心室卸载前后的患者,并使用左心室辅助装置(LVAD)。使用末端脱氧核苷酸转移酶脱氧尿苷三磷酸-生物素缺口末端标记(TUNEL)技术检查了LVAD植入时从左心尖去除的组织的凋亡情况。在患者接受LVAD治疗99 +/- 20(SEM)天后,再检查在心脏移植时移植的这些相同心脏的细胞凋亡。另有10名同样严重的心力衰竭患者在不使用LVAD的情况下进行了心脏移植,作为对照。死后约6小时从死于非心血管疾病原因的患者的尸体解剖中获得的八颗心用作非心力衰竭对照。另外,在LVAD之前和之后,通过免疫组织化学检查了6个心脏的抗凋亡蛋白Bcl-2,以及修复和/或增殖标志物,增殖细胞核抗原(PCNA)。 LVAD植入时,在8名患者心脏的组织切片中未检测到凋亡。这些患者中只有1例在LVAD插入后具有有限的凋亡(<1个凋亡细胞/ 1,000个心肌细胞)。 10例严重心力衰竭患者中有3例未接受LVAD但接受了移植治疗,显示出有限的凋亡(<1个凋亡细胞/ 1,000个心肌细胞)。同样,死于非心血管疾病患者的对照心脏均未显示凋亡。 LVAD插入时6例患者中有6例Bcl-2过表达。在所有这些患者中,心脏慢性负荷后,Bcl-2恢复到可以忽略的水平。同样,在LVAD植入时,PCNA在6个衰竭心脏中的5个中大量表达,而在LVAD慢性卸载后,在5个心脏中的4个中表达降低。结论:凋亡是在人的心脏衰竭中罕见或不一致的发现。通过使用诸如LVAD之类的机械设备优化左心室负荷条件,可以改变诸如Bcl-2和PNCA等细胞应激和DNA复制和/或修复等细胞应激指标的过表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号